|
|
Office Locations:
|
100 Bayview Circle, Ste 5600
Newport Beach, CA 92660
Phone: 949-872-2552
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Formed in 2014, CureDuchenne Ventures is the investment arm of CureDuchenne, a national nonprofit dedicated to curing Duchenne muscular dystrophy, the most common and lethal form of muscular dystrophy. The firm's early funding helps Duchenne science attract future investments made by VC firms, biotech companies, and pharmaceutical companies. CureDuchenne Ventures funding opportunities range from $50K-$5M, and 100% of proceeds from equity positions in companies are reinvested to support research into next-generation technologies. As of 2017, CureDuchenne's portfolio includes 12 wide-ranging projects with 3 successful exits. Investments from CureDuchenne Ventures have successfully leveraged more than $2.9 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies to fund emerging projects to find treatments for Duchenne.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
